Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Open Access
- 19 August 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 3 (8) , e222685
Abstract
The US Food and Drug Administration (FDA) created the accelerated approval pathway in 1992 to speed approval of drugs for serious diseases on the basis of surrogate end points “reasonably likely to predict clinical benefit.”1 The use of accelerated approval has increased over the past years, particularly for cancer drugs.2 In 2020, 53% of cancer drugs were approved by the FDA through accelerated approval.3 The comparable pathway in the European Union (EU) is conditional marketing authorization, which was implemented in 2006.4 The European Medicines Agency (EMA) only grants conditional marketing authorization to first (and not supplemental) indications.5 Another notable difference is the time limitation of conditional marketing authorization, which must be renewed annually with an application and interim report on outstanding study obligations.5Keywords
This publication has 13 references indexed in Scilit:
- Accelerated Approval Is Not Conditional ApprovalJAMA Oncology, 2022
- Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval PathwayJAMA Internal Medicine, 2021
- Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational studyBMJ, 2021
- Revisiting FDA Approval of AducanumabNew England Journal of Medicine, 2021
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort studyBMJ, 2020
- FDA Approval and Regulation of Pharmaceuticals, 1983-2018JAMA, 2020
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated ApprovalJAMA Internal Medicine, 2019
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and BiologicsJAMA Oncology, 2018
- Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic reviewBMJ, 2017
- Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort studyBMJ Open, 2017